Connor, Clark & Lunn Investment Management (CC&L)’s Keros Therapeutics KROS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Sell	127,885 -129,999	-50%	-$1.45M	﹤0.01%	1109
2026 Q1	$2.85M	Sell	257,884 -63,462	-20%	-$980K	0.01%	854
2025 Q4	$6.54M	Sell	321,346 -13,808	-4%	-$242K	0.02%	575
2025 Q3	$5.3M	Buy	335,154 +69,447	+26%	+$1.03M	0.02%	561
2025 Q2	$3.55M	Buy	265,707 +137,604	+107%	+$1.86M	0.01%	678
2025 Q1	$1.31M	Buy	128,103 +98,957	+340%	+$1.15M	0.01%	865
2024 Q4	$461K	Buy	+29,146	New	+$1.51M	﹤0.01%	1162
2022 Q4	–	Sell	-9,620	Closed	-$362K	–	1329
2022 Q3	$362K	Buy	+9,620	New	+$333K	﹤0.01%	880

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KROS Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Keros Therapeutics (KROS) stake by 50% in Q2 2026, selling an estimated $1.45M and leaving 127,885 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KROS in Q3 2022 and has held it in 8 quarters since. The position peaked at $6.54M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 127,885 shares of Keros Therapeutics worth $1.37M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 129,999 Keros Therapeutics shares in Q2 2026, an estimated $1.45M.
Keros Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1109 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Keros Therapeutics in Q3 2022 and has held it in 8 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Keros Therapeutics position peaked at $6.54M in Q4 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.